ITM Isotope Technologies Munich (ITM) and its oncology therapeutics division, Lumara Bio, presented new data on their investigational lutetium-177 (Lu-177)-edotreotide (ITM-11) radiopharmaceutical at the American Society for Radiation Oncology (ASTRO) 2026 annual meeting in Boston.
One poster featured a retrospective analysis of 49 adults with metastatic, well-differentiated, somatostatin receptor-positiveastroenteropancreatic neuroendocrine tumors (GEP-NETs) from the SwissNET registry in Switzerland. Patients re-treated with Lu-177-edotreotide after disease progression (Group A, n=37) had a longer median real-world progression-free survival of 12.5 months, compared with 4.8 months for those given a non-radiopharmaceutical systemic therapy (Group B, n=12; p < 0.001). Median overall survival was 90.1 months in Group A versus 39.8 months in Group B (p < 0.001), according to the companies.
A second poster reported dosimetry results from substudy A of ITM's phase 3 COMPETE trial, which evaluated absorbed radiation doses in healthy organs across 17 patients and in tumor lesions across nine patients. Tumor absorbed dose was significantly higher than dose to normal organs, kidney absorbed dose coefficients remained consistent with a median intra-patient variability of 14%, and tumor-to-kidney dose ratios stayed above 1 across all treatment cycles, the vendors said.
